Hepatitis C (englisch)

Safety and efficacy of triple therapy containing boceprevir (BOC) or telaprevir (TVR) plus peginterferon alfa-2a / ribavirin in patients with advanced fibrosis or cirrhosis in real-life setting, Mauss et al. . . . vorgestellt anlässlich des Liver Meeting of the American Association for the Study of Liver Diseases 2013 (AASLD) in Washington, DC, (USA)

Zurück